{
    "clinical_study": {
        "@rank": "157945", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Volunteers (ABT-494)", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dosing of ABT-494 in healthy volunteers"
            }, 
            {
                "arm_group_label": "Rheumatoid Arthritis Patients", 
                "arm_group_type": "Experimental", 
                "description": "Multiple dosing of ABT-494 in patients with rheumatoid arthritis"
            }, 
            {
                "arm_group_label": "No treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administration in healthy volunteers and patients with rheumatoid arthritis"
            }, 
            {
                "arm_group_label": "Healthy Volunteers (tofa)", 
                "arm_group_type": "Other", 
                "description": "Multiple dosing of tofacitinib in healthy volunteers"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose\n      study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and\n      multiple dose study in healthy volunteers."
        }, 
        "brief_title": "A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the safety, tolerability and pharmacokinetics of ABT-494 in healthy volunteers and\n      in patients with rheumatoid arthritis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy Volunteers:\n\n          -  Male and female subjects 18 to 55 years of age, inclusive.\n\n          -  Subject is judged to be in good general health.\n\n        Rheumatoid Arthritis Patients:\n\n          -  Male and female patients 18 to 75 years of age, inclusive.\n\n          -  Subject has a diagnosis of rheumatoid arthritis for at least six months.\n\n          -  Subject has been on methotrexate therapy for at least three months and on a stable\n             dose for at least four weeks.\n\n        Exclusion Criteria:\n\n          -  History or evidence of active or latent tuberculosis.\n\n          -  History or significant allergic reaction to any drug.\n\n          -  Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or\n             within 5 half-lives of the respective medication, whichever is longer.\n\n          -  Current or expected need for oral intake of at least 10 mg prednisone per day or\n             equivalent corticosteroid therapy.\n\n          -  History of acute inflammatory joint disease of different origin other than rheumatoid\n             arthritis (rheumatoid arthritis patients)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741493", 
            "org_study_id": "M13-845"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Healthy Volunteers (ABT-494)", 
                    "Rheumatoid Arthritis Patients"
                ], 
                "description": "Oral administration of ABT-494 capsules", 
                "intervention_name": "ABT-494", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "No treatment", 
                "description": "Oral administration of placebo capsules", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Healthy Volunteers (tofa)", 
                "description": "Oral administration", 
                "intervention_name": "Tofacitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Methotrexate", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Safety", 
            "Tofacitinib"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Site Reference ID/Investigator# 95817"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Site Reference ID/Investigator# 95816"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Site Reference ID/Investigator# 95815"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78744"
                    }, 
                    "name": "Site Reference ID/Investigator# 92153"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orem", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84058"
                    }, 
                    "name": "Site Reference ID/Investigator# 97177"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Steven  Jungerwirth, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number and percentage of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose up to 28 days after the last dose of study drug"
            }, 
            {
                "description": "Blood pressure, pulse rate and body temperature", 
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose up to 28 days after the last dose of study drug"
            }, 
            {
                "description": "Hematology, Chemistry, and Urinalysis", 
                "measure": "Clinical Lab testing", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose up to 28 days after the last dose of study drug"
            }, 
            {
                "description": "ECGs done in triplicate; heart rate, PR interval, QT/QTc interval and QRS duration", 
                "measure": "Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to first dose, during first dose interval, prior to last dose and until 24 hours post last dose"
            }, 
            {
                "description": "Cmax, Tmax, AUC, elimination rate constant and half-life", 
                "measure": "Pharmacokinetics of ABT-494", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up to 72 hours after the last dose of ABT-494"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741493"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Cmax, Tmax, AUC, elimination rate constant and half-life", 
            "measure": "Pharmacokinetics of Methotrexate", 
            "safety_issue": "No", 
            "time_frame": "Prior to first dose up to 48 hours after the last dose of methotrexate"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}